APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study
consists of the dose escalation stage and the dose expansion stage.